James Chambliss, MD
Family Medicine · Magnolia, ARNPI 1285856971
Payments from drug & device makers
Across 195 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$444
- Takeda Pharmaceuticals U.S.A., Inc.$309
- Astellas Pharma US Inc$277
- Novartis$236
- Novo Nordisk$227
- Lilly USA, LLC$210
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,90794%
- Education$2006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $444 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $309 |
| Astellas Pharma US Inc | 6 | $277 |
| Novartis | 17 | $236 |
| Novo Nordisk | 15 | $227 |
| Lilly USA, LLC | 14 | $210 |
| GSK | 12 | $200 |
| Pfizer | 13 | $199 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $111 |
| Merck | 6 | $101 |
| Amgen | 6 | $86 |
| Bayer | 5 | $74 |
| Exact Sciences | 4 | $72 |
| AstraZeneca | 5 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Boehringer Ingelheim | 3 | $47 |
| Johnson & Johnson | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Genentech USA, Inc. | 2 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Dexcom, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
How this compares
$3,107 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 88 | $113,208 |
| EliquisApixaban | 145 | $92,589 |
| JardianceEmpagliflozin | 66 | $52,091 |
| OzempicSemaglutide | 54 | $51,611 |
| TrulicityDulaglutide | 41 | $47,306 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $34,259 |
| EntrestoSacubitril/Valsartan | 51 | $31,105 |
| Xtampza ErOxycodone Myristate | 13 | $26,621 |
| FarxigaDapagliflozin Propanediol | 42 | $26,226 |
| JanuviaSitagliptin Phosphate | 24 | $24,190 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 576 | $22,216 |
| VraylarCariprazine Hcl | 15 | $21,687 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,424 |
| LinzessLinaclotide | 33 | $21,217 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $20,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $210 | $160,513129 claims |
| PfizerEliquis | $199 | $92,589145 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $47 | $68,036107 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $63 | $57,05587 claims |
| AbbVieVraylar, Linzess, Lumigan, Synthroid | $444 | $52,485111 claims |
| Novo NordiskOzempic | $227 | $51,61154 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $200 | $33,36850 claims |
| NovartisEntresto | $236 | $31,10551 claims |
| MerckJanuvia | $101 | $24,19024 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $18 | $22,94558 claims |
| Astellas Pharma US IncMyrbetriq | $277 | $13,58428 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $309 | $5,42211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Magnolia
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.